Optiscan Imaging Launches InSpecta Veterinary Imaging Device in US; Shares Hit 1.5-Year High

MT Newswires Live
Jul 07

Optiscan Imaging (ASX:OIL) said it has launched InSpecta, its veterinary-first microscopic imaging device, in the US after successfully submitting its regulatory documents to the US Food and Drug Administration (FDA) Center for Veterinary Medicine, according to a Tuesday Australian bourse filing.

The company said InSpecta creates a new in-house imaging capability for veterinary practices, supporting faster clinical insight, workflow efficiency, and potential new revenue opportunities.

The launch means Optiscan has brought its first clinical device to market, creating a regulatory pathway that should support future product submissions, it added.

The company's shares rose 11% in recent Tuesday trade and earlier hit their highest price since February 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10